Cancer Vaccines Market Size, Share, By Treatment Method (Therapeutic Cancer Vaccines, and Preventive Cancer Vaccines), Technology (Whole-Cell Cancer Vaccines, Recombinant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and Others), Route of Administration (Intravenous (IV) Administration, Subcutaneous Injection, Intramuscular Injection, Oral Delivery System, and Others), Indication (Cervical Cancer, Prostate Cancer, Bladder Cancer, Melanoma, and Others), Distribution Channel (Hospitals, Government Organization, Healthcare Institutions, and Others), and Region - Trends, Analysis, and Forecast till 2035

• The cancer vaccines market size is expected to increase at a rate of USD 37.1 Billion by 2035.
• In 2024, the target market was valued at USD 9.2 Billion.
• The market is growing at a CAGR of 15.1%.

Cancer vaccines is a type of immunotherapy which is designed to treat or prevent cancer by simulating the body’s immune system to recognize and destroy cancer cells. Cancer vaccines specifically designed to target proteins and molecules that found on cancer cells. Cancer vaccines are mainly categorized into preventive vaccines and therapeutic vaccines. Preventive vaccines designed to prevent cancers before development, while therapeutic vaccines designed to treat existing cancer by stimulating immune system to attack and destroy cancer cells.

The increasing prevalence of cancer and rising demand for personalized treatment are the driving factors driving the target market. The development, production, and commercialization of vaccines to treat cancer, resulting to drive cancer vaccines market growth.

Impact of AI in Cancer Vaccines Market:

Artificial intelligence (AI) significantly impacting cancer vaccines market by enabling the development of highly personalized vaccine through the analysis of large datasets to improve patient outcomes and accelerating the development process. AI algorithms can analyze a patient’s tumor genome to identify mutation that trigger an immune response. AI models can predict epitopes which can be recognized by immune system to optimize targeting antigens for cancer vaccines.

Key Drivers of Target Market:

Rising Research & Development Investment is Propelling the Market Growth

Increasing research and development investment by pharmaceutical companies or research foundation help for the growth and expansion of cancer vaccines market. Increased R&D investment allow to explore new technologies and platforms for cancer vaccines development including, mRNA vaccines, viral-vector based vaccines, and DNA vaccines. Thus, advancement in research is anticipated to growth of cancer vaccines market share.

• For instance, in March 2024, Researchers at the University of Oxford, the Francis Crick Institute and University College London had granted USD 1.7 Million of funding from Cancer Research U.K. and the CRIS Cancer Foundation to develop a lung cancer vaccine. The team will receive funding for the study over the next 2 years to support lab research and initial manufacturing of 3,000 doses of the vaccine at the Oxford Clinical Bio Manufacturing Facility.

Restraints:

Complex Manufacturing and Supply Chain Challenges Limits Growth of Target Market

Production of cancer vaccines on a large scale can be complex, which requires specialized facilities and supply chain management. Cancer vaccine production depends on a global supply chain for raw materials, components and equipment. Disruption in supply chain such as, shortages of essential materials, global crises can delay vaccine producing, resulting to disturb cancer vaccines market growth.

• Counterbalance Statements: Advances in bio manufacturing technologies such as cell-based production system, continuous manufacturing methods and improve logistics, this can help to improve production process, and reduce manufacturing costs. Improve manufacturing techniques to reduce costs, reduce dependence of raw materials and increase availability of cancer vaccine globally.

Opportunities & Market Trends:

Increasing Research and Development Field Advancements in Immunotherapy Fuels Market Expansion

Advancement in immunotherapy offer alternative to traditional therapies, such as chemotherapy and radiation. Advancement in immunotherapy developed checkpoint inhibitors that work by blocking certain proteins on immune cells that inhibit the immune system’s ability to attack tumors. The growing emphasis on immunotherapy treatment that used body’s immune system to fight against cancer, which is driving factor for cancer vaccine development. Cancer vaccines are widely dependents on immunotherapy field, which is rapidly growing and gaining acceptance in oncology treatment, resulting to drive cancer vaccines market growth in upcoming years.

• For instance, according to the article published by Moffitt Cancer Center in March 2024, advancements in pancreatic cancer vaccines through immunotherapy treatment. Pancreatic cancer, known for its aggressiveness and limited treatment options, presents a daunting challenge to both patients and medical professionals. The immunotherapy boost patient’s immune system to specifically target and attack pancreatic tumors and destroy tumor cells. These treatments offer new hope for a more targeted, effective, and personalized approach to combating pancreatic cancer.

The cancer vaccines market is segmented into treatment method, technology, indication, route of administration, distribution channel, and region.

Treatment Method:

By treatment method, the target market are classified into therapeutic cancer vaccines, preventive cancer vaccines, and others. The preventive cancer vaccines segment holds a dominant cancer vaccines market share due to growing initiative about the prevention of cancer among manufacturers, government and various healthcare organization. Preventive vaccines are designed to prevent cancer from developing at the initial stage, leading to growth of cancer vaccines market share.

Technology:

By technology, the cancer vaccines market is divided into whole-cell cancer vaccines, recombinant cancer vaccines, viral vector & DNA cancer vaccines, and others. The recombinant cancer vaccines is dominating in the target market as the major key players operating in the market are focusing more on developing vaccines through recombinant technologies. These vaccines have ability to generate immune response, based on individual patients’ mutation in their tumor to enhance specificity and effectiveness for destroying cancer cells. The rising demand for therapeutic vaccine for treatment resulting to drive cancer vaccines market growth.

• For instance, in September 2024, MSD Pharmaceutical got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to update the prescribing information of the Human Papillomavirus (HPV) 9-valent Recombinant Vaccine. HPV is the recombinant vaccine help to protect individuals against 9 types of HPV such as, cervical, vaginal, and vulvar cancers in female and anal cancer, certain head & neck cancers, mouth cancer, genital warts in both males and females.

Route of Administration:

Cancer vaccines market, by route of administration, is divided into intravenous (IV) administration, subcutaneous injection, and intramuscular injection, oral delivery system, and others. The intramuscular vaccines dominate the target market due to it is most commonly used method cancer vaccine administration. Intramuscular (IM) injection deliver the vaccine directly into the muscle tissue, where it is absorbed slowly by immune system and give effectively strong immune responses.

Indication:

By indication, the focused market is segmented into cervical cancer, prostate cancer, bladder cancer, melanoma, and others. The cervical cancer hold the largest cancer vaccines market share due to rising prevalence of this cancer. Cervical cancer is associated with human papillomavirus (HPV), which is responsible for almost all cervical cancer cases. The growing demand for HPV vaccines and HPV’s role in cervical cancer lead to growth of cancer vaccines market size.

• For instance, according to data published by World Health Organization, in March 2024, cervical cancer is the fourth most common cancer in women globally with around 660,000 new cases and around 350,000 deaths in 2022. The highest rates of cervical cancer incidence and mortality are in low- and middle-income countries. This reflects major inequities driven by lack of access to national HPV vaccination, cervical screening and treatment services and social and economic determinants.

Distribution Channel:

By distribution channel, the market is segmented into, hospitals, government organization, healthcare institutions, and others. The hospitals segment dominate the target market as it is considered as primary source for cancer screening and treatment. Hospitals are equipped with necessary infrastructure, trained medical professionals and technologies to handle advanced treatments. The high availability and supply of vaccines products in hospitals and patients’ preference for vaccine uptake in well-equipped healthcare centers, resulting to drive cancer vaccine market share.

Region:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This region hold the largest share of 37.3% and is expected to dominate region over the forecast period. The rising burden of cancer, increasing research & development, and growing healthcare infrastructure are drive the target market. Government are focusing on improving healthcare infrastructure and rising investment in cancer care are anticipated to growth of cancer vaccines market in the region.

• For instance, according to data published by National Cancer Institute, in 2024, an estimated 2,001,140 new cases of cancer will be diagnosed in the United States and 611,720 people will die from the disease. The most common cancers are breast cancer, prostate cancer, lung and bronchus cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, and others. Approximately 40.5% of men and women are diagnosed with cancer at some point during their lifetimes.

Asia Pacific: This is the fastest growing region in target market. The rapid development of cancer vaccines and various initiatives are investing in research & development field for innovation of advanced vaccines leading to growth of target market. The rising healthcare improvements, and increasing cancer awareness in countries such as China, Japan and India, are creating unique opportunities for treatment development, resulting to drive cancer vaccines market in upcoming years.

Cancer Vaccines Market Report Scope:

Segmentation:

By Treatment Method:

• Therapeutic Cancer Vaccines
• Preventive Cancer Vaccines

By Technology:

• Whole-Cell Cancer Vaccines
• Recombinant Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines
• Others

By Route of Administration:

• Intravenous (IV) Administration
• Subcutaneous Injection
• Intramuscular Injection
• Oral Delivery System
• Others

By Indication:

• Cervical Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Others

By Distribution Channel:

• Hospitals
• Government Organization
• Healthcare Institutions
• Others

 By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the cancer vaccines market include Merck & Co., Inc., GSK plc, Dendreon Pharmaceuticals LLC., and others. These key players are focusing on improving on research and development, innovative strategies, new product launches, strategic partnerships and acquisitions to enhance product offering through collaborations.

List of Key Players in the Market:

• Merck & Co., Inc.
• GSK plc
• Dendreon Pharmaceuticals LLC.
• JW CreaGene
• Serum Institute of India Pvt. Ltd.
• Verity Pharmaceuticals, Inc.
• Wantai BioPharm
• Vaccinogen
• BioNTech SE
• ose-immuno
• OBI Pharma
• Shanghai Bovax Biotechnology Co., Ltd.
• Moderna, Inc.
• Sanofi
• AstraZeneca

• In August 2024, BioNTech announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the treatment of non-small cell lung cancer (NSCLC). BNT116 aimed to introduce in immune system to tumor markers associated with NSCLC. These vaccines detect and destroy cancer cells.  The trial was conducted across seven countries and involve approximately 130 patients with varying stages of lung cancer, from early to advanced or recurrent types. The BNT116 has the potential to decrease lung cancer recurrence, and improve long-term survival rated for patients.
• In March 2024, Merck announced plans to initiate clinical development of a new investigational multi-valent HPV vaccines designed to provide protection against multiple HPV types. The increasing number of cervical cancers, showing importance of GARDASIL and GARDASIL 9 to public health. To address the increasing global demand for GARDASIL and GARDASIL 9 and support broader and equitable access, Merck has made significant investments in manufacturing to help increase supply.

Analyst View:

The increasing incidence of myeloma & Subcutaneous Injection and proliferation of sequencing techniques, including recombinant cancer vaccines, viral vector & DNA cancer vaccines, aimed to enhance the accuracy and accessibility of molecular diagnostics for hematologic cancer. The increasing research & development and rising investment of key players for innovation in technologies, leading to growth of cancer vaccines market.

More Related Reports

Travel Vaccines Market
Typhoid Fever Vaccines Market
Pediatric Vaccines Market
Recombinant DNA technology Market
T4 DNA Ligase Market